Product Description
OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oxagen
Company Location: RANDOLPH VT 05060
Company CEO: Robert Wolfe
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Total Knee Arthroplasty
Phase 3: Asthma
Phase 2: Asthma|Rhinitis, Allergic|Pulmonary Eosinophilia|Eosinophilic Esophagitis|Dermatitis, Atopic|Common Cold|Picornaviridae Infections|Inflammation
Phase 1: Healthy Volunteers|Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Orbital Fractures |
2022-08-15 |
|
| 2018-003548-22 | P3 |
Completed |
Asthma |
2021-02-01 |
|
| RG1005365 | P4 |
Not yet recruiting |
Total Knee Arthroplasty |
2020-12-18 |
|
| OC000459/019/15 | P2 |
Completed |
Asthma|Inflammation|Pulmonary Eosinophilia |
2018-08-02 |
32% |